Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer.

Timothée DavidAude MallavialleJulien FagetLindsay B AlcarazMarion LapierrePénélope Desroys du RoureValérie Laurent-MathaHanane MansouriMarta JarlierPierre MartineauPascal RogerSéverine GuiuThierry ChardèsEmmanuelle Liaudet-Coopman

Published in: British journal of pharmacology (2023)

Anti-CathD antibody-based therapy triggers the anti-tumour innate and adaptive immunity in preclinical models of BC, and is a promising immunotherapy for immunogenic TNBC.

Keyphrases

immune response
mesenchymal stem cells
bone marrow